{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:03:26Z","timestamp":1771063406634,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clcc.2020.04.007","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:48:17Z","timestamp":1591922897000},"page":"e189-e199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism"],"prefix":"10.1016","volume":"19","author":[{"given":"Alexandre A.","family":"J\u00e1come","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Ohinata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armeen","family":"Mahvash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fogelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole D.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.04.007_bib1","first-page":"191","article-title":"How to approach thrombocytopenia","volume":"2012","author":"Stasi","year":"2012","journal-title":"ASH Education Program Book"},{"key":"10.1016\/j.clcc.2020.04.007_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1532\/LH96.04010","article-title":"Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race","volume":"10","author":"Cheng","year":"2004","journal-title":"Lab Hematol"},{"key":"10.1016\/j.clcc.2020.04.007_bib3","series-title":"Wintrobe\u2019s Clinical Hematology","author":"Arber","year":"2013"},{"key":"10.1016\/j.clcc.2020.04.007_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.04.007_bib5","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Overman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.04.007_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.510230326","article-title":"Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease","volume":"23","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2020.04.007_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib9","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2020.04.007_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejso.2007.09.007","article-title":"Effect of preoperative chemotherapy on liver resection for colorectal liver metastases","volume":"34","author":"Mehta","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2020.04.007_bib13","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000210025","article-title":"Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer","volume":"76","author":"Angitapalli","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2020.04.007_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2020.04.007_bib16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2020.04.007_bib17","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2005.05.059","article-title":"Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial","volume":"23","author":"Bonneterre","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.2005.11.140","volume":"23","author":"Ardizzoni","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib19","doi-asserted-by":"crossref","first-page":"e21478","DOI":"10.1371\/journal.pone.0021478","article-title":"A\u00a0transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations","volume":"6","author":"May","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2020.04.007_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1478-3231.2003.00880.x","article-title":"Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells","volume":"23","author":"Yokomori","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.clcc.2020.04.007_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/djx288","article-title":"The addition of bevacizumab to oxaliplatin-based chemotherapy: impact upon hepatic sinusoidal injury and thrombocytopenia","volume":"110","author":"Overman","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2020.04.007_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejso.2013.12.009","article-title":"Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"40","author":"Imai","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2020.04.007_bib23","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2020.04.007_bib24","first-page":"1953","article-title":"Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy","volume":"34","author":"Arakawa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2020.04.007_bib25","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2012.07.004","article-title":"Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9","volume":"57","author":"Nakamura","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clcc.2020.04.007_bib26","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2020.04.007_bib27","doi-asserted-by":"crossref","first-page":"e16978","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2020.04.007_bib28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00535-012-0563-6","article-title":"Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study","volume":"47","author":"Hidaka","year":"2012","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.clcc.2020.04.007_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jss.2014.08.052","article-title":"Regorafenib suppresses sinusoidal obstruction syndrome in rats","volume":"193","author":"Okuno","year":"2015","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.clcc.2020.04.007_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/000313481708300323","article-title":"Partial splenic artery embolization to treat hypersplenism secondary to hepatic cirrhosis: a meta-analysis","volume":"83","author":"Wang","year":"2017","journal-title":"Am Surg"},{"key":"10.1016\/j.clcc.2020.04.007_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00330-015-3839-4","article-title":"Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications","volume":"26","author":"Cai","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clcc.2020.04.007_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2214\/ajr.179.5.1791323","article-title":"Long-term results of initial and repeated partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"179","author":"Kimura","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clcc.2020.04.007_bib33","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/cncr.23432","article-title":"Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy","volume":"112","author":"Kauffman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2020.04.007_bib34","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/cam4.856","article-title":"Partial splenic embolization to permit continuation of systemic chemotherapy","volume":"5","author":"Luz","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clcc.2020.04.007_bib35","first-page":"3527","article-title":"Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients","volume":"26","author":"Passhak","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2020.04.007_bib36","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00268-009-0095-2","article-title":"Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients","volume":"33","author":"Amin","year":"2009","journal-title":"World J Surg"},{"key":"10.1016\/j.clcc.2020.04.007_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.diii.2014.08.005","article-title":"Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment","volume":"96","author":"Beji","year":"2015","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.clcc.2020.04.007_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.dld.2008.10.005","article-title":"Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients","volume":"41","author":"Zhu","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clcc.2020.04.007_bib39","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3748\/wjg.v18.i24.3138","article-title":"Comparison of total splenic artery embolization and partial splenic embolization for hypersplenism","volume":"18","author":"He","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2020.04.007_bib40","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.1997.15.11.3368","article-title":"Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin","volume":"15","author":"Isaacs","year":"1997","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:35Z","timestamp":1761519995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820300657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1533002820300657"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.04.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}